SCHEMBL6413545

SCHEMBL6413545

CC(=O)N(C)Cc1ccccc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 1/20 0.49
TSHR P16473 2/20 0.47
TAAR1 Q96RJ0 3/20 0.47
HPGD P15428 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
NFKB1 P19838 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 2/20 0.42
BLM P54132 1/20 0.42
RIPK1 Q13546 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 3/20 0.39
PKM P14618 1/20 0.39
CHRM2 P08172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15269326 0.85 HPGD (0.54) PYCR1TSHRTAAR1HPGDCYP1A2
SCHEMBL31719788 0.82 TAAR1 (0.62) PYCR1TSHRTAAR1HPGDCYP1A2
SCHEMBL2818877 0.82 PYCR1 (0.46) PYCR1TSHRTAAR1HPGDCYP1A2
SCHEMBL14143465 0.81 RIPK1 (0.45) HPGDLMNARIPK1KMT2ASMN1; SMN2
SCHEMBL26921107 0.80 NPC1 (0.49) PYCR1TSHRTAAR1HPGDCYP1A2
Hydrochloric Acid SCHEMBL5191489 0.80 AOC3 (0.49) PYCR1TSHRTAAR1HPGDLMNA
SCHEMBL13322844 0.79 AKR1B1 (0.48) TSHRTAAR1HPGDCYP2D6RIPK1
SCHEMBL15224082 0.79 ALDH1A1 (0.47) TSHRLMNARIPK1KMT2ASMN1; SMN2
SCHEMBL13114704 0.79 HSP90AA1 (0.52) HPGDKMT2ASMN1; SMN2POLBMAPT
SCHEMBL8195952 0.79 RAB9A (0.42) PYCR1TSHRTAAR1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
EP-1322599-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-02 EP disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed
WO-2001096283-A9 HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-10-17 WO disclosed
WO-2001096283-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 PYCR1 341/4885TSHR 2150/4885TAAR1 2056/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 PYCR1 344/4885TSHR 3659/4885TAAR1 2149/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 PYCR1 344/4885TSHR 3659/4885TAAR1 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.